Our data suggest that treatment with TRPV4 antagonists would potentially be more beneficial in a hyper-inflammatory phase of sepsis compared to a phase of a compensatory anti-inflammatory response or a mixed anti-inflammatory response. The gene discussed is TRPV4; the disease is Sepsis.